Cassava Sciences Inc. Common Stock (NASDAQ: SAVA)
36 Days left to seek lead plaintiff status.
The Complaint alleges Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true capabilities of Cassava’s drugs; notably, that Company simply did not have a drug that was capable of abating the progression of Alzheimer’s Disease.